Track market-moving stories before they get noisy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Considering buying MKTX stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

Milestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months.

EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial was featured in an oral plenary session at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in February 2026. The presentation highlighted strong clinical performance in the first milestone readout of EXPAND, as well as the study’s rigorous design, including confirmation of all outcomes against genetic truth.

Fetal Focus provides fetal risk assessment for 21 genes associated with serious, early-onset medical conditions. The test is an option for pregnant patients who test positive with Natera’s Horizon™ carrier screen when the father is unavailable for guideline-recommended carrier testing.1

It incorporates Natera’s proprietary ultra-sensitive LinkedSNP™ technology to determine whether a fetus has inherited disease-causing variants from one or both parents. In difficult homozygous cases, where the child inherits the same variant from both parents, Natera’s technology has performed well, identifying 5 out of 5 such cases.2-3

“In developing Fetal Focus, our goal has been to expand the scope of what noninvasive prenatal testing can deliver,” said Sheetal Parmar, SVP of Medical Affairs, Women’s Health at Natera. “With more than 2,000 patients enrolled, EXPAND is helping to set a new standard for clinical evidence in single-gene NIPT, and we remain focused on generating high-quality data to support clinicians and the families they serve.”

References

ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880. Accessed May 2026. About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

Key Takeaways NTRA's EXPAND trial for Fetal Focus single-gene NIPT passed 2,000 patients, more than doubling over 12 months.EXPAND data were presented at the February 2026 SMFM meeting, with genetic confirmation of outcomes.Natera says LinkedSNP can detect inherited variants, identifying all five complex homozygous cases so far. Natera (NTRA - Free Report) recently announced that its EXPAND clinical trial evaluating the Fetal Focus single-gene noninvasive prenatal test (NIPT) has exceeded 2,000 patients, representing more than a twofold increase over the past year.

The milestone comes shortly after positive EXPAND data were presented during an oral plenary session at the Society for Maternal-Fetal Medicine Annual Meeting in February 2026. The data showcased clinical performance in the first milestone readout of EXPAND and emphasized the trial’s robust design, including genetic confirmation of all outcomes.

Per management, the company developed Fetal Focus to expand the scope of noninvasive prenatal testing. Enrollment of more than 2,000 patients strengthens EXPAND’s role in establishing a new standard for clinical evidence in single-gene NIPT while supporting clinicians and families with high-quality data.

Likely Trend of NTRA Stock Following the NewsFollowing the announcement, the company's shares gained 4.5% at yesterday’s closing. In the year-to-date period, shares of the company have fallen 10.6% compared with the industry’s 11.2% decline. However, the S&P 500 has risen 8.1% in the same timeframe.

The enrollment milestone and clinical validation of Fetal Focus may strengthen investor confidence in Natera’s women’s health portfolio. Positive clinical data and expanding physician awareness could support broader adoption of single-gene NIPT solutions, potentially enhancing the company’s competitive position in the prenatal diagnostics market.

NTRA currently has a market capitalization of $28.08 billion.

Image Source: Zacks Investment Research

More on the NewsEXPAND is a prospective, blinded, multi-site clinical trial designed to evaluate the clinical performance of Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). Fetal Focus provides fetal risk assessment for 21 genes associated with severe early-onset genetic conditions. The test is intended for pregnant patients who receive a positive result on Natera’s Horizon carrier screening test when paternal carrier testing is unavailable.

Natera’s proprietary ultra-sensitive LinkedSNP technology determines whether disease-causing variants have been inherited from one or both parents. The technology has demonstrated strong performance in complex homozygous cases, successfully identifying all five such cases evaluated to date.

Industry Prospects Favoring the MarketGoing by the data provided by Coherent Market Insights, the non-invasive prenatal testing market is valued at $5.62 billion in 2026 and is expected to witness a CAGR of 10.6% through 2033.

Factors like the increasing prevalence of chromosomal abnormalities among newborns and growing awareness and acceptance of non-invasive prenatal testing methods are driving the market’s growth.

Other NewsNatera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%. Fetal fraction refers to the proportion of placental DNA circulating.

Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting strong operational momentum and market demand. Despite ongoing unprofitability, margin improvements and analyst consensus point toward profitability by FY28, supported by upward earnings revisions.

-

Signatera™ will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer

SIGNAL is a new group of Natera-sponsored interventional trials designed to establish the clinical utility of MRD-guided treatment de-escalation strategies across multiple cancer types

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer.

The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediate-risk, hormone receptor (HR) positive, HER2 negative, early stage breast cancer. This is despite the fact that only ~3% of eligible patients derive benefit, over 60% of patients experience serious adverse events,1-2 and the U.S. retail costs can be over $400,000 for a full course of treatment. Meanwhile, data presented at SABCS 2025 from the PALLAS trial show that HR+ breast cancer patients who tested MRD-negative with Signatera had excellent long-term outcomes, with >95% distant recurrence-free interval at 5 years. This suggests that MRD-negative patients can safely defer CDK4/6 inhibition with no impact to clinical outcomes, with the provision that it be added if and when MRD is detected on serial testing using a TOMR (Treatment on MRD) approach.

SIGNAL-ER 101 plans to enroll approximately 725 patients across 50 sites in the United States. Patients who test MRD-positive will receive endocrine therapy plus CDK4/6 inhibitors, while those who test MRD-negative (the vast majority of patients) will receive endocrine therapy alone with quarterly Signatera monitoring. Patients who become MRD-positive during surveillance will be eligible to initiate CDK4/6 inhibition at that time, consistent with the TOMR approach.

“Many women with this type and stage of breast cancer are overtreated, which can have a profound impact on their quality of life,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection at Natera. “SIGNAL-ER 101 is a key part of our evidence generation roadmap, to support Signatera-guided treatment optimization without compromising the survival benefit from CDK4/6 inhibitors. This approach also allows patients to get the most effective treatment when Signatera shows it is necessary.”

SIGNAL-ER 101 is the first in a series of innovative Natera-sponsored SIGNAL trials across multiple cancer types, designed to demonstrate that MRD-negative patients may be able to delay or defer treatment. There are many instances of overtreatment in cancer. This concept has already been studied in the IMvigor011 trial where MRD-negative patients with muscle-invasive bladder cancer achieved 97% overall survival at 2 years without any adjuvant therapy, and in the GALAXY and CALGB/SWOG 80702 trials, where MRD-negative patients with colorectal cancer saw no clinical benefit from adjuvant chemotherapy and celecoxib, respectively.

References

Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2023;24(1):77-90. doi:10.1016/S1470-2045(22)00694-5. Slamon DJ, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. New England Journal of Medicine. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488. About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology C

It’s hard to pick just one favorite stock idea for the rest of the year. It’s been a blistering-hot 2026, as the AI revolution keeps rolling ahead. And while memory and storage stocks have been the trade of the first half, questions linger as to what kinds of names could offer the best risk/reward, not just for H2 2026, but perhaps for the next 18 months and beyond.

Of course, it’s been a fantastic time to be a momentum investor, but, in my view, I think that taking a step back to consider lesser-appreciated corners of the market could be the best way to play Wayne Gretzky’s playbook of skating to where the puck is heading next.

Not to shoot down hopes of further gains in the likes of Micron (NASDAQ:MU | MU Price Prediction), which some analysts think could rise above the $1,600 mark, but I do think that those not comfortable with the state of the DRAM trade might find it wise to consider the other corners of the market that AI could touch and even transform in a profound way.

In my view, looking at the companies making use of applied AI could be in for significant spoils over the long term. While their shares might be less heated than DRAM or NAND plays, let’s just say I like the price of admission, how AI is actually being applied to the field, and the magnitude of rewards to be had if the technology advances along an exponential curve.

Natera stock could be the hidden AI stock that’s not yet fully appreciated by Wall Street Enter shares of Natera (NASDAQ:NTRA), a biotech company that I think should come up whenever applied AI is brought up. As others look at the swelling demand for chips, I’m looking for companies that can actually deliver ROIs. And when it comes to ROIs, perhaps there’s no better place to look than among applied AI innovators in genomics.

For those unfamiliar with the name, it’s a leading innovator in cell-free DNA (cfDNA) technology. In other words, it’s tiny bits of DNA floating in one’s bloodstream. Indeed, when it comes to the bull case for the rise of AI, its application to cure cancer is often brought up as the number one narrative to keep advancing the technology in spite of its risks. And while Natera doesn’t have the cure, it does stand out when it comes to detection. The first step is early detection.

Of course, detecting cancer with a blood test is difficult, given the amount of noise in a blood sample. Not to mention, a tiny piece of a tumor’s DNA would represent such a tiny (one molecule per 10,000), almost unnoticeable part of one’s blood. In other words, it’s too tiny to even be noticed. But it’s a great problem for AI to help tackle.

As the company makes good use of Nvidia‘s (NASDAQ:NVDA) helping hand (remember that it’s one of Nvidia’s many partners in applied AI), the firm stands to make use of a powerful trove of data. All the tumor genomes and all those blood draws are profoundly powerful for training an applied AI model.

One of the widest data moats around It’s also a source of a moat. Data is the new oil, gold, or, in today’s era, where it’s harder and more expensive to obtain DRAM, memory chips. Whether we’re talking about the oncological applications or other areas, Natera is a hyper-growth company worthy of any radar, especially if you buy the “eliminating cancer” narrative.

The $30.6 billion company is hard to value after correcting from its January high. Now down around 16% from its peak, perhaps there’s an opportunity to buy. For those who choose to enter the name at around $213 per share, one will be in good company alongside big-name investors, including Stanley Druckenmiller’s Duquesne Family Office, which topped up its position in Q1 and, at the time, held the name as its largest holding.

At a time when investors want to see ROI, I think it’s time to look to the companies with huge TAMs and the right partnerships that are already putting AI to work. When it comes to “liquid biopsies” for cancer detection and beyond, I think the TAM has the potential to be quite sizeable. Natera stands out for its profound vision and its underestimated moat that, I think, will allow it to excel in AI-driven ROI.

-

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company’s board of directors.

“Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board,” said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. “Their deep expertise across evidence generation, clinical development, biopharma, and leading cancer research institutions will be incredibly valuable as Natera continues expanding the impact of precision diagnostics in patient care.”

“The oncology field is moving toward more personalized and data-driven treatment decisions, and molecular diagnostics will play a critical role in that evolution,” said Dr. Lynch. “Natera has established itself as a leader in this space, and I’m excited to help support the company’s next phase of innovation and impact.”

“It’s an honor to join Natera’s Board of Directors,” said Dr. Rubin. “Natera has built an exceptionally strong scientific and clinical foundation, and I look forward to supporting the company as it continues advancing molecular diagnostics and expanding the clinical evidence supporting precision oncology.”

Dr. Lynch has joined the Human Capital Committee, and Dr. Rubin has joined the Nominating, Corporate Governance and Compliance Committee.

Biographical Information

Thomas Lynch Jr., M.D., is a world-renowned scientist, highly respected oncologist and successful NCI-designated comprehensive cancer center leader. As the President and Director of Fred Hutch Cancer Center, and holder of the Raisbeck Endowed Chair, Dr. Lynch brings more than three decades of experience at highly regarded U.S. cancer centers. He has expertise in solid tumor research, precision medicine and discoveries in fundamental biology. Before joining Fred Hutch, Dr. Lynch held leadership roles as CSO at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief at Yale’s Smilow Cancer Hospital, as well as chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and The Washington State Academy of Sciences.

Eric Rubin, M.D., brings more than 35 years of experience in cancer drug development across academic and industry settings, including leading large-scale oncology clinical programs. Most recently, he was senior vice president of global clinical oncology at Merck, where he held several senior leadership roles during his 16-year tenure and led the initial development of KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Earlier in his career, Dr. Rubin served as a faculty member at Dana-Farber Cancer Institute and later as director of the investigational therapeutics division at Rutgers Cancer Institute of New Jersey, where his research focused on oncology translational science. He has authored more than 100 peer-reviewed publications and served on numerous national research and policy committees, including study sections for the National Cancer Institute and American Cancer Society, as well as program committees for the American Association for Cancer Research and the American Society of Clinical Oncology.

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insi.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

MongoDB (NASDAQ:MDB | MDB Price Prediction) is back in every AI database headline after a 12.24% EPS beat and a first-ever Rule of 40 quarter. But here’s what you should actually be watching.

With Fed Chair Kevin Warsh now prioritizing structural price stability over speculative market support, the long-duration, money-losing momentum trade is precisely the wrong place to hide. MongoDB still carries a trailing EPS of -$0.88, a price-to-sales ratio of 10.66, an EV/Revenue of 9.7, and a forward P/E of 56x. The growth that supposedly justifies that multiple is decelerating in plain sight: FY27 revenue guidance of $2.86B–$2.90B implies 16–18% growth, a notable step down from FY26’s 22.79%. The shares are already down 22.29% year-to-date and sit well below the 200-day moving average of $322.39. Add a new CEO in CJ Desai following Dev Ittycheria’s 11-year tenure, the flagged departures of the CRO and President of Field Operations, and buybacks executed at an average of $171.84 and $221.86 per share into a falling share price, and you have a crowded AI trade priced for a future that the company itself is guiding lower.

Now turn to Cognizant (NASDAQ:CTSH), trading at $52.75 with a P/E of 11, a forward P/E of 9, and a 2.45% dividend yield. Three points carry the case.

One: durable free cash flow generation. Cognizant generated $2.665 billion in free cash flow in 2025, up 45.87% year over year, with operating cash flow of $2.883 billion against capital expenditures of only $288 million. FCF conversion ran 120% of net income. That cash is funding $1.6 billion in planned 2026 shareholder returns, including $1 billion in buybacks and a 6.5% dividend hike to $0.33 per quarter.

Two: accelerating fundamentals while MongoDB decelerates. Q1 2026 revenue rose 5.8% to $5.413 billion, adjusted EPS of $1.40 beat consensus of $1.33, and bookings grew 21% year over year to a $29.60 billion trailing total at a 1.4x book-to-bill. Management raised full-year revenue guidance to $22.11–$22.64 billion and operating margin to 16.0–16.2%, with Project Leap targeting $200–$300 million in in-year savings.

Three: the underappreciated AI stack. Cognizant is a named scaling partner for OpenAI’s Codex, a Diamond partner with Google Cloud running a dedicated Gemini Enterprise practice, and is partnered with Palantir, Anthropic, and Microsoft Azure. The AI Lab holds 65 U.S. patents, and nearly 40% of code is AI-assisted. CEO Ravi Kumar S notes the company returned to the “winner’s circle” two years ahead of the target set at Investor Day.

Analysts carry an average target of $72.52 with 11 Buy and 2 Strong Buy ratings, against shares trading 35.72% lower year-to-date. Retirement-focused investors should put MongoDB on the watchlist and Cognizant on the research-priority list this week.

Key Takeaways MDB revenues climbed 25% to $687.6M, driven by strong Atlas subscription growth.MongoDB ended Q1 with more than 67,700 customers and 121% net ARR expansion.MDB raised fiscal 2027 guidance after stronger profitability and free cash flow growth. MongoDB, Inc.(MDB - Free Report) delivered first-quarter fiscal 2027 non-GAAP earnings of $1.32 per share, up 32% year over year and beating the Zacks Consensus Estimate by 11.86%.

Total revenues increased 25.3% year over year to $687.62 million and surpassed the consensus estimate by 3.84%.

Segment-wise, subscription revenues rose 25% year over year to $666.1 million, representing the dominant share of total revenues. Services revenues increased 22% year over year to $21.5 million, reflecting continued strength in the company’s subscription-led business model.

Within subscription revenues, Atlas-related revenues totaled $512.5 million, while MongoDB Enterprise Advanced and other revenues were $153.7 million. Management noted that Atlas represented roughly three-quarters of total first-quarter revenues, underscoring the continued momentum in the company’s cloud platform business.

MDB’s Q1 Customer MetricsThe company ended the fiscal first quarter with more than 67,700 customers, up from 57,100 in the prior-year period, adding 2,500 customers sequentially during the quarter.

Atlas customers exceeded 66,400 by the end of the quarter, increasing from 55,800 in the year-ago period.

In the first quarter of fiscal 2027, MongoDB had 2,895 customers with annual recurring revenues of at least $100,000, up from 2,506 in the prior-year quarter. Revenue growth from this cohort outpaced overall company revenue growth, reflecting sustained enterprise adoption.

The company also highlighted expanding platform adoption, with 45% of Atlas customers generating at least $100,000 in ARR using two or more features compared with 37% in the prior-year quarter. Total company net ARR expansion improved to 121%, reflecting healthy customer consumption trends.

Operating Details of MDBIn the fiscal first quarter, MongoDB’s non-GAAP gross profit was $512.2 million, while the non-GAAP gross margin remained stable year over year at 74%.

Non-GAAP sales and marketing expenses increased 18.6% year over year to $214.7 million. Sales and marketing expenses, as a percentage of revenues, decreased 170 basis points (bps) year over year to 31.2%.

Non-GAAP research and development expenses grew 26.5% on a year-over-year basis to $127.1 million. Research and development, as a percentage of revenues, increased 20 bps year over year to 18.5%.

Non-GAAP general and administrative expenses rose 25.5% year over year, reaching $47.3 million in the reported quarter. General and administrative expenses, as a percentage of revenues, remained the same year over year to 6.9%.

MongoDB reported non-GAAP income from operations of $123.2 million, up from $87.4 million in the prior-year quarter. The non-GAAP operating margin expanded to 18% from 16%, reflecting improved operating leverage and continued revenue strength.

MongoDB's Balance Sheet & Cash FlowAs of April 30, 2026, MongoDB had cash, cash equivalents and short-term investments of $2.4 billion compared with $2.4 billion as of Jan. 31, 2026.

Operating cash flow was $201.6 million in the fiscal first quarter, up from $179.6 million reported in the prior quarter.

Free cash flow during the quarter was $197.5 million compared with $105.9 million in the prior quarter.

MongoDB Raises Fiscal 2027 GuidanceFor the second-quarter fiscal 2027, MongoDB expects revenues between $729 million and $734 million. Non-GAAP earnings are projected in the range of $1.58 to $1.61 per share.

For fiscal 2027, MongoDB now anticipates revenues between $2.92 billion and $2.96 billion. Non-GAAP earnings are expected between $5.95 and $6.14 per share following the company’s stronger-than-expected first-quarter performance.

MDB’s Zacks Rank & Stocks to ConsiderMongoDB currently carries a Zacks Rank #3 (Hold).

Micron Technology (MU - Free Report) , Ciena (CIEN - Free Report) and Amphenol (APH - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Computer and Technology sector. MU and CIEN each sport a Zacks Rank #1 (Strong Buy), while APH carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Micron Technology shares have soared 225% in the year-to-date period. The company is scheduled to release third-quarter fiscal 2026 results on June 24.

Ciena shares have returned 143.9% in the year-to-date period. The company is set to report second-quarter fiscal 2026 results on June 4.

Amphenol shares have gained 9.3% in the year-to-date period. The company is expected to report second-quarter fiscal 2026 results on July 29.

Software stocks have had a brutal first five months of 2026, with many of them falling sharply even as the S&P 500 has risen. Snowflake (SNOW 1.16%), despite management describing its artificial intelligence (AI) data cloud as a beneficiary of the AI boom, has seen its shares fall alongside other software stocks this year amid investor concern that AI would disrupt software companies overall. Indeed, at one point in April, the stock sat more than 50% below where it had traded a year earlier. But the stock is rebounding now. In fact, the stock is now up sharply year to date, helped mainly by the market's reaction to the tech company's better-than-expected earnings report last week.

But is this news about more than Snowflake? Could there be more software companies that, like Snowflake, will actually benefit more from AI than they will be hurt by it? Snowflake's latest report is the loudest evidence yet that the market may have had it backward.

Image source: Getty Images.

Snowflake reaccelerates The company's fiscal first-quarter results (the period ended April 30, 2026) certainly didn't paint a picture of AI disrupting software. On the contrary, the business saw a significant acceleration.

The company's fiscal first-quarter product revenue, which accounts for the bulk of its total revenue, rose 34% year over year to $1.33 billion -- an acceleration from 30% in fiscal Q4 and 26% in the year-ago quarter. Additionally, management said this was the strongest sequential dollar growth in company history.

Further, Snowflake's acceleration is happening broadly across its business. Net revenue retention, which measures spending from existing customers against the prior year, ticked up from 125% in the prior quarter to 126%. And the company's remaining performance obligations (RPO), which represent contracted revenue not yet recognized, grew 38% year over year to $9.21 billion. Additionally, the company added 616 net new customers -- up 38% from a year ago.

Profitability is improving alongside the growth. Snowflake's non-GAAP (adjusted) operating margin expanded to 12% from 9%, and adjusted earnings per share rose to $0.39 from $0.24.

What's driving the inflection is AI, and not in the way some bears may have feared. Rather than displacing Snowflake's core platform, AI is pulling more data and more workloads onto it. The company's newer agentic products -- Snowflake Intelligence and its coding agent, Cortex Code -- are showing strong traction. And these offerings, in turn, are helping drive greater consumption.

"AI is accelerating the value that people can get from the data that they have put into Snowflake or that they can put into Snowflake," said CEO Sridhar Ramaswamy in the company's fiscal first-quarter earnings call.

Confident enough in the demand, management lifted its full-year product revenue guidance to $5.84 billion, or 31% growth, up from prior guidance of $5.66 billion and 27% growth. The company also signed a new $6 billion five-year agreement with Amazon's Amazon Web Services and expanded its partnership with OpenAI.

Today's Change

(

-1.16

%) $

-2.79

Current Price

$

237.60

The group is turning -- but tread carefully Snowflake isn't alone.

Observability specialist Datadog (DDOG 1.46%) got there first. Its first-quarter 2026 revenue rose 32% year over year to just over $1 billion -- the company's first billion-dollar quarter -- accelerating from 29% in the prior quarter and 25% a year earlier. Datadog raised its full-year outlook, too, and its stock has climbed more than 80% in 2026, trading near a 52-week high. The thesis is similar to Snowflake's: AI makes software systems more complex, and more complexity means more to monitor.

Database company MongoDB (MDB 1.27%) rounds out the picture. Its fiscal first-quarter revenue (the period ended April 30, 2026) rose 25% to $687.6 million, with its cloud database, Atlas, up 29% and now roughly three-quarters of total revenue. MongoDB raised its full-year revenue guidance as well, and shares continued higher the day after the report -- a sharp turn for a stock that was down more than 20% earlier in the year.

So, some of the laggards are no longer lagging -- and others in the software space may not have fully recovered the year's losses but have rebounded sharply from their lowest points.

The catch is that the rebound is well along, and the easy gains may already be behind.

For instance, Snowflake's stock surged about 35% in a single session after the report, its best day ever, and trades near $255 as of this writing -- back within reach of its 52-week high after a brutal stretch. Up about 16.5% in 2026, it is now significantly outperforming the S&P 500 year to date.

But the growth stock's valuation now leaves little slack. Snowflake remains unprofitable on a generally accepted accounting principles (GAAP) basis, with the bottom line still deep in the red. Further, the stock's price-to-sales ratio now sits at 17 -- a steep valuation multiple that assumes the reacceleration holds for years, and that the company is able to begin reporting substantial profits -- profits that grow at strong rates for years.

Furthermore, investors should keep in mind that Snowflake's consumption model can swing both ways: revenue tracks how much customers actually use the platform, so if enterprise AI spending cools later this year, growth could quickly fade without any change in customer count.

Overall, Snowflake's business looks healthier than it has in a while, and the read-through for software in general is starting to look encouraging. But after a run-up like this, shares of Snowflake (and shares of other software stocks that have sharply rebounded over the last few weeks) simply may no longer be the bargains they were.

Regarding Snowflake stock specifically, I think the recent rebound has already more than priced in the change in sentiment for the company's future.

, /PRNewswire/ -- MongoDB, Inc. (NASDAQ: MDB) today announced that it will present at three upcoming conferences: the William Blair 46th Annual Growth Stock Conference in Chicago, IL, the Bank of America Global Technology Conference in San Francisco, CA, and the D.A. Davidson Conference in Nashville, TN.

Mike Berry, Chief Financial Officer, and Ben Cefalo, Chief Product Officer, Core Products, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June, 2, 2026 at 9:20 AM Central Time (10:20 AM Eastern Time). Mike Berry, Chief Financial Officer, and Ben Cefalo, Chief Product Officer, Core Products, will present at the Bank of America Global Technology Conference on Wednesday, June 3, 2026 at 9:20 AM Pacific Time (12:20 PM Eastern Time). Mike Berry, Chief Financial Officer, will present at the D.A. Davidson Technology & Consumer Conference on Thursday, June 11, 2026 at 8:45 AM Central Time (9:45 AM Eastern Time). A live webcast of each presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcasts will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB's mission is to empower innovators to create, transform, and disrupt industries with software. MongoDB's unified data platform was built to power the next generation of applications, and MongoDB is the most widely available, globally distributed database on the market. With integrated capabilities for operational data, search, real-time analytics, and AI-powered data retrieval, MongoDB helps organizations everywhere move faster, innovate more efficiently, and simplify complex architectures. Millions of developers and more than 67,000 customers across industries —including approximately 75% of the Fortune 100—rely on MongoDB for their most important applications. To learn more, visit mongodb.com.

Investor Relations
Jess Lubert
[email protected]

Media Relations
MongoDB
[email protected]

SOURCE MongoDB, Inc.

Also from this source

MongoDB, Inc. (MDB) Presents at 46th Annual William Blair Growth Stock Conference Transcript

MongoDB, Inc. (MDB) Presents at Bank of America 2026 Global Technology Conference Transcript

Choosing between Snowflake (SNOW 1.16%) and MongoDB (MDB 1.27%) involves weighing massive data warehousing scale against flexible database agility. Both companies are pivotal to the modern cloud ecosystem for retail investors.

Snowflake specializes in centralizing fragmented data across different cloud providers, while MongoDB offers a flexible document database that developers love for building modern applications. As enterprises prioritize digital transformation and artificial intelligence, both companies serve as critical infrastructure. This comparison evaluates their financials and valuations to see which represents a better opportunity today.

The case for SnowflakeSnowflake provides its AI Data Cloud, a platform used for data engineering and analytics. The company serves 790 of the Forbes Global 2000 firms and has over 733 customers that contribute more than $1 million in annual product revenue. As organizations worldwide increasingly invest in tech stocks to modernize their data stacks, the company continues to expand its reach across multiple public clouds. It effectively helps businesses break down data silos to gain better insights.

In FY 2026, revenue reached nearly $4.7 billion, representing a growth rate of roughly 29.2% over the $3.6 billion reported in the prior year. Despite this robust top-line growth, the company reported a net loss of approximately $1.3 billion for the period. This resulted in a net margin of negative 28.4%, indicating the company is still prioritizing heavy research and market expansion over immediate bottom-line profitability.

As of its January 2026 balance sheet, the debt-to-equity ratio is roughly 1.4x, which compares total debt to shareholder equity. The current ratio of approximately 1.3x indicates the company has $1.30 in short-term assets for every dollar of short-term liabilities. Free cash flow was nearly $1.1 billion, but note that stock-based compensation represented roughly 130.9% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

The case for MongoDBMongoDB offers a modern database platform that helps organizations build and run cloud-based applications. It serves over 65,200 customers across various industries, including a large share of the Fortune 100. The business relies heavily on MongoDB Atlas, its fully managed cloud database service designed for scale and developer flexibility. This cloud-first strategy enables the company to easily reach a global developer base.

For FY 2026, the company generated roughly $2.5 billion in revenue, which is a 22.8% increase from the prior fiscal year’s revenue of $2.0 billion. It reported a net loss of nearly $71.2 million, showing significant improvement from the $129.1 million loss in the previous year. This performance led to a net margin of negative 2.9%, as the company continues to narrow its losses and move toward break-even.

The balance sheet as of January 2026 shows a debt-to-equity ratio of approximately 0.0x, indicating the company carries almost no debt relative to its shareholder equity. Its current ratio of nearly 4.7x suggests a very high level of short-term liquidity compared to its immediate obligations. Free cash flow reached approximately $500.2 million, though note that stock-based compensation represented roughly 109.0% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

Risk profile comparisonSnowflake faces intense competition from established cloud giants like Amazon (AMZN 2.10%), Microsoft (MSFT 0.75%), and Alphabet (GOOG +0.77%) (GOOGL +1.33%), which may bundle competing services. The company also faces cybersecurity risks following unauthorized access to customer accounts in 2024, which damaged its reputation. Furthermore, its heavy reliance on Amazon’s infrastructure means any changes to that relationship could disrupt operations.

MongoDB faces similar pressure from legacy database providers such as IBM (IBM 0.89%), Oracle (ORCL 1.21%), and Microsoft, which have vast resources. The company is also highly dependent on its Atlas product, and any failure to maintain its adoption would significantly impact revenue. Additionally, the legal uncertainty surrounding its server-side public license could potentially hinder future adoption by developers or enterprise clients.

Valuation comparisonMongoDB appears to offer a more conservative entry point for investors, as it trades at a lower valuation relative to both sales and future earnings estimates. The forward P/E, which compares the stock price to future earnings estimates, and the P/S ratio, which measures price against annual sales, help evaluate these companies.

MetricSnowflakeMongoDBSector BenchmarkForward P/E128.5x60.1x43.1xP/S ratio18.3x12.0xSector benchmark uses the SPDR XLK sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

MongoDB and Snowflake have much in common. Both are benefiting from the AI boom and ubiquitous cloud-based data solutions. But they differ in many respects as well, which makes all the difference when it comes to attracting investors.

Snowflake’s business involves enterprise data management, and with its AI Data Cloud platform, it has become a leader in the industry. It has partnered with major tech companies and has seen accelerating revenue growth. But it appears that this growth expectation is reflected in the share price.

MongoDB’s database platform is gaining popularity for building modern applications. And yes, this includes those applications powered by AI. Its flagship Atlas cloud platform is seeing growing demand. Recent earnings results show that organizations are still spending on AI infrastructure despite economic uncertainty, and MongoDB is well positioned to benefit.

From my perspective, there’s nothing wrong with an investment in Snowflake except for its rich valuation. So, I’d choose MongoDB. Along with its more reasonable valuation, it offers exposure to AI and significant growth potential. If it keeps moving in its current direction, long-term investors should be rewarded.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of MongoDB, Inc. (NASDAQ: MDB) breached their fiduciary duties to shareholders.

If you currently own MongoDB stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

MongoDB, Inc. (MDB) Presents at D.A. Davidson 2nd Annual Technology & Consumer Conference 2026 Transcript

-

NEW YORK--(BUSINESS WIRE)--CRH (NYSE: CRH), the leading provider of building materials, will publish its Q1 2026 financial results before market open on Thursday, Apr. 30, 2026, in advance of a conference call and webcast presentation at 8:00 a.m. (EDT).

CRH's results and the related presentation will be available at www.crh.com/investors/results-presentations.

Registrations for the event can be made at www.crh.com/investors. Upon registration a link to join the call and dial-in details will be made available.

A replay of the webcast will be available on www.crh.com.

About CRH

CRH is the leading provider of building materials critical to modernizing infrastructure. With our team of 83,000 people across 4,000 locations, our unmatched scale, connected portfolio, and deep local relationships make us the partner of choice for transportation, water, and reindustrialization projects, shaping communities for a better tomorrow. CRH (NYSE: CRH) is a member of the S&P 500 Index. For more information, visit www.crh.com.

More News From CRH

Back to Newsroom

-

NEW YORK--(BUSINESS WIRE)--Further to the announcement made on March 13, 2026, CRH (NYSE: CRH) today confirms that the listings of its ordinary shares and its 7% preference shares on the official list of the UK Financial Conduct Authority, and the admission to trading of those shares on the main market for listed securities of the London Stock Exchange, have both been cancelled with effect from 08:00 a.m. (London) today, April 20, 2026.

CRH’s ordinary shares are now solely listed on the New York Stock Exchange.

Frequently Asked Questions and Shareholder Helpline

A FAQ document for shareholders holding ordinary shares is available at https://www.crh.com/investors/ordinary-shareholders/. A FAQ document for shareholders holding 7% preference shares is available at https://www.crh.com/investors/preference-shareholders/. A helpline is also available to assist shareholders, the contact details for which are included in the FAQ documents.

About CRH

CRH is the leading provider of building materials critical to modernizing infrastructure. With our team of 83,000 people across 4,000 locations, our unmatched scale, connected portfolio, and deep local relationships make us the partner of choice for transportation, water, and reindustrialization projects, shaping communities for a better tomorrow. CRH (NYSE: CRH) is a member of the S&P 500 Index. For more information, visit www.crh.com.

More News From CRH

Back to Newsroom

Posted by Defense World Staff on Apr 21st, 2026

AE Wealth Management LLC decreased its holdings in Crh Plc (NYSE:CRH – Free Report) by 33.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,428 shares of the construction company’s stock after selling 10,741 shares during the period. AE Wealth Management LLC’s holdings in CRH were worth $2,674,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of CRH. Artisan Partners Limited Partnership bought a new stake in shares of CRH in the third quarter worth $295,798,000. Alkeon Capital Management LLC bought a new stake in shares of CRH in the third quarter worth $209,825,000. SG Americas Securities LLC grew its holdings in shares of CRH by 9,615.1% in the fourth quarter. SG Americas Securities LLC now owns 1,386,928 shares of the construction company’s stock worth $173,089,000 after acquiring an additional 1,372,652 shares during the period. Citigroup Inc. grew its holdings in shares of CRH by 229.0% in the third quarter. Citigroup Inc. now owns 1,811,126 shares of the construction company’s stock worth $217,154,000 after acquiring an additional 1,260,558 shares during the period. Finally, Qube Research & Technologies Ltd grew its holdings in shares of CRH by 53.8% in the third quarter. Qube Research & Technologies Ltd now owns 3,336,263 shares of the construction company’s stock worth $400,018,000 after acquiring an additional 1,167,309 shares during the period. Institutional investors own 62.50% of the company’s stock.

CRH Stock Up 1.3% Shares of CRH stock opened at $118.53 on Tuesday. The stock’s 50-day simple moving average is $112.54 and its 200-day simple moving average is $117.94. Crh Plc has a 52 week low of $81.60 and a 52 week high of $131.55. The company has a market capitalization of $79.21 billion, a price-to-earnings ratio of 21.47, a PEG ratio of 2.04 and a beta of 1.35.

CRH (NYSE:CRH – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The construction company reported $1.52 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.68). CRH had a net margin of 10.02% and a return on equity of 15.98%. The business had revenue of $9.42 billion during the quarter, compared to analysts’ expectations of $11.15 billion. During the same quarter in the previous year, the firm earned $1.02 earnings per share. CRH’s revenue was up 6.2% on a year-over-year basis. On average, equities analysts expect that Crh Plc will post 5.97 earnings per share for the current year.

CRH Increases Dividend The company also recently announced a quarterly dividend, which was paid on Wednesday, April 8th. Investors of record on Friday, March 6th were given a $0.39 dividend. This is an increase from CRH’s previous quarterly dividend of $0.37. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date was Friday, March 6th. CRH’s dividend payout ratio (DPR) is presently 28.26%.

Analyst Ratings Changes Several analysts recently commented on the company. Wells Fargo & Company lifted their price objective on CRH from $133.00 to $135.00 and gave the stock an “equal weight” rating in a report on Friday, February 20th. JPMorgan Chase & Co. lifted their price objective on CRH from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Morgan Stanley reissued an “overweight” rating and set a $139.00 price target on shares of CRH in a report on Wednesday, April 15th. Citigroup boosted their price target on CRH from $142.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, DA Davidson set a $120.00 price target on CRH in a report on Friday, February 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $139.54.

Check Out Our Latest Analysis on CRH

About CRH (Free Report)

CRH plc, originally formed as Cement Roadstone Holdings in 1970 and headquartered in Dublin, Ireland, is a global building materials group. The company has grown from its Irish roots into one of the largest international suppliers of construction materials, expanding primarily through acquisitions and regional business development. CRH operates an integrated network of manufacturing and distribution businesses that serve both public and private construction markets.

CRH’s core activities include the production and distribution of aggregates, cement, asphalt, ready-mixed concrete and other bulk materials, together with a broad range of value-added building products such as precast concrete, masonry, bricks, roofing products, pipe and drainage systems, and construction accessories.

See Also Five stocks we like better than CRH

Receive News & Ratings for CRH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAble Wealth Management LLC Increases Holdings in JPMorgan Ultra-Short Municipal ETF $JMST

NEXT HEADLINE »Able Wealth Management LLC Boosts Position in JPMorgan U.S. Quality Factor ETF $JQUA

CRH (NYSE:CRH – Get Free Report) and Grafton Group (OTCMKTS:GROUF – Get Free Report) are both construction companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Profitability This table compares CRH and Grafton Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets CRH 10.02% 15.98% 6.78% Grafton Group N/A N/A N/A Earnings and Valuation This table compares CRH and Grafton Group”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRH $37.45 billion 2.11 $3.73 billion $5.52 21.37 Grafton Group $3.32 billion 0.73 $180.09 million N/A N/A CRH has higher revenue and earnings than Grafton Group.

Risk & Volatility CRH has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Grafton Group has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Institutional and Insider Ownership 62.5% of CRH shares are held by institutional investors. Comparatively, 8.2% of Grafton Group shares are held by institutional investors. 0.1% of CRH shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations This is a breakdown of recent ratings and target prices for CRH and Grafton Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRH 0 3 13 2 2.94 Grafton Group 0 0 1 0 3.00 CRH presently has a consensus target price of $139.54, suggesting a potential upside of 18.27%. Given CRH’s higher probable upside, research analysts clearly believe CRH is more favorable than Grafton Group.

Summary CRH beats Grafton Group on 12 of the 13 factors compared between the two stocks.

About CRH (Get Free Report)

CRH plc, together with its subsidiaries, provides building materials solutions in Ireland and internationally. It operates through four segments: Americas Materials Solutions, Americas Building Solutions, Europe Materials Solutions, and Europe Building Solutions. The company provides solutions for the construction and maintenance of public infrastructure and commercial and residential buildings; and produces and sells aggregates, cement, readymixed concrete, and asphalt, as well as provides paving and construction services. It also manufactures, supplies, and delivers solutions for the built environment in communities across North America; and offers building and infrastructure solutions serving complex critical utility infrastructure, such as water, energy, transportation, and telecommunications projects, and outdoor living solutions for enhancing private and public spaces. In addition, the company combines materials, products, and services to produce a wide range of architectural and infrastructural solutions for use in the building and renovation of critical utility infrastructure, commercial and residential buildings, and outdoor living spaces for the built environment. Further, it produces and supplies precast and pre-stressed concrete products comprising floor and wall elements, beams, vaults, pipes, and manholes; granite, limestone, and sandstone; concrete and polymer-based products, such as underground vaults, drainage systems, utility enclosures, and modular precast structures; engineered steel, polymer-based anchoring, fixing, and connecting solutions; concrete masonry, hardscape and related products, including pavers, blocks and curbs, retaining walls, and slabs; and fencing and railing systems, composite decking, lawn and garden products, and packaged concrete mixes. The company was founded in 1936 and is headquartered in Dublin, Ireland.

About Grafton Group (Get Free Report)

Grafton Group plc engages in the distribution, retailing, and manufacturing businesses in Ireland, the Netherlands, Finland, and the United Kingdom. Its Distribution segment distributes building materials, paint, tools, ironmongery, fixings, and accessories, workwear and PPE, and spare parts; materials and plant for mechanical services, heating, plumbing, and air movement; and trade, DIY, and self-build markets with building materials, timber, doors and floors, plumbing and heating, bathrooms, and landscaping products under the Selco, Leyland SDM, Chadwicks, MacBlair, Isero, Polvo, Gunters en Meuser, TG Lynes, and IKH brands. The company’s Retailing segment retails home and garden products through stores, including DIY products, paints, lighting products, homestyle products, housewares, bathroom products, and kitchens, as well as gardening and Christmas products under the Woodie’s brand. Its Manufacturing segment manufactures dry mortars and wooden staircases; and drainage, ducting and roofline systems under the CPI Mortar, StairBox, and MFP brand names. Grafton Group plc was founded in 1902 and is based in Dublin, Ireland.

Receive News & Ratings for CRH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK--(BUSINESS WIRE)--CRH (NYSE: CRH), the leading provider of building materials, today reported first quarter 2026 financial results. Total revenues of $7.4 billion (Q1 2025: $6.8 billion) were 9% ahead of the prior year driven by positive underlying demand, disciplined commercial execution, and contributions from acquisitions. Net loss of ($0.2) billion (Q1 2025: ($0.1) billion) was higher than the prior year, driven by higher depreciation and impairment charges as well as increased interest expense, net. Adjusted EBITDA* of $0.6 billion (Q1 2025: $0.5 billion) increased by 18% over the prior year, reflecting strong operational discipline and contributions from acquisitions. CRH’s net loss margin of (2.4%) was below the prior year net loss margin of (1.5%), while Adjusted EBITDA margin* of 8.0% (Q1 2025: 7.3%) was ahead of the prior year.

Jim Mintern, Chief Executive Officer, stated “We delivered a strong start to 2026, reflecting good momentum from early-season project activity, disciplined commercial execution and positive contributions from acquisitions. During the quarter, we continued our active portfolio management, reallocating capital into higher-growth, more connected businesses. Notwithstanding the current geopolitical and macroeconomic uncertainty, we are encouraged by the continued strength of underlying demand across our key markets. The outlook for our business remains positive and backed by our superior strategy and connected portfolio we are pleased to reaffirm our financial guidance for 2026, leaving us well positioned for another year of growth and value creation ahead.”

Summary Financials

Q1 2026

YoY Change

Total revenues

$7.4bn

+9%

Net loss

($0.2bn)

(84%)

Net loss margin

(2.4%)

(90bps)

Adjusted EBITDA*

$0.6bn

+18%

Adjusted EBITDA margin*

8.0%

+70bps

Diluted Loss Per Share

($0.27)

(80%)

Diluted Loss Per Share pre-impairment*

($0.20)

(33%)

Three months ended March 31, 2026

Americas Materials Solutions' Total revenues were 21% ahead of the first quarter of 2025, driven by strong underlying demand and contributions from acquisitions. Adjusted EBITDA increased by 75% year-over-year, reflecting good commercial execution, disciplined cost management and contributions from acquisitions.

Americas Building Solutions' Total revenues were 1% behind the first quarter of 2025, driven by subdued new-build residential demand and adverse weather conditions, partly offset by contributions from acquisitions. Adjusted EBITDA was in line with the prior year, supported by strong cost control, performance improvement initiatives and contributions from acquisitions.

International Solutions' Total revenues were 5% ahead of the first quarter of 2025, as contributions from acquisitions, positive pricing momentum, and currency tailwinds more than offset weather-impacted volumes and the impact of divestitures. Adjusted EBITDA was 32% ahead of the prior year, driven by operational efficiencies and portfolio optimization.

Please refer to Appendix 1 on pages 5 to 6 for detailed business segment information for the three months ended March 31, 2026.

Acquisitions and Divestitures

CRH has a proven track record of allocating capital into high-growth connected opportunities that maximize value for shareholders. In the first quarter of 2026, CRH completed five value-accretive acquisitions for total consideration of $0.1 billion, compared with $0.6 billion in the same period of 2025. A further three acquisitions were completed in April for total consideration of $0.1 billion. Cash proceeds from divestitures and disposals of long-lived assets were $34 million, compared with $107 million in the first quarter of 2025.

The Company has entered into an agreement to acquire Axius Water, a leading provider of specialized water quality solutions in North America, for a consideration of $0.7 billion, with the transaction expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. This acquisition is expected to strengthen CRH’s position as a leading water infrastructure player in the United States.

CRH has also agreed to divest of three non-core businesses: its construction accessories operations for a consideration of $0.7 billion, its lawn and garden operations for a consideration of $1.1 billion, and MoistureShield, a manufacturer of composite decking for a consideration of $0.1 billion. The MoistureShield transaction closed on April 6, while the construction accessories and lawn and garden transactions are expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals.

Other Financial Items

Depreciation, depletion and amortization charges of $0.6 billion were $0.1 billion higher than the prior year (Q1 2025: $0.5 billion), primarily due to the impact of acquisitions and higher growth capital expenditure.

Loss on impairments was $48 million (Q1 2025: $nil million), related to the agreed divestiture of the construction accessories operations.

Interest income of $21 million was lower than the comparable period (Q1 2025: $37 million), primarily due to lower interest rates and principal on deposit. Interest expense of $203 million was higher than the comparable period (Q1 2025: $181 million), primarily due to an increase in gross debt balances.

Income tax benefit of $55 million (Q1 2025: $58 million) was lower than the prior year.

Other nonoperating expense, net, was $4 million, a decrease from the comparable period (Q1 2025: $20 million), primarily due to the non‑recurrence of the prior year loss on divestitures.

Diluted Loss Per Share of ($0.27) was behind the prior year (Q1 2025: ($0.15)), primarily due to higher depreciation and impairment charges as well as higher interest expense, net. Diluted Loss Per Share pre-impairment* of ($0.20) was lower than the prior year (Q1 2025: ($0.15)).

Balance Sheet and Liquidity

Total short and long-term debt was $18.5 billion at March 31, 2026, compared with $17.7 billion at December 31, 2025.

Net Debt* at March 31, 2026, was $15.8 billion, compared to $14.2 billion at December 31, 2025. The increase in Net Debt* is driven by the seasonal net cash outflow from operating activities, as well as acquisitions, cash returns to shareholders through continued share buybacks and the purchase of property, plant and equipment in the quarter. CRH ended Q1 2026 with $3.3 billion of cash and cash equivalents and restricted cash on hand (Q1 2025: $3.4 billion) as well as $4.5 billion of undrawn committed facilities available until May 2030. CRH remains committed to maintaining its robust balance sheet and expects to maintain a strong investment-grade credit rating.

Dividends and Share Buybacks

In line with its policy of consistent long-term dividend growth, on April 30, 2026, CRH announced a quarterly dividend of $0.39 per share, representing a 5% increase on the prior year. The dividend will be paid on June 17, 2026, to shareholders registered at the close of business on May 15, 2026.

CRH continued its ongoing share buyback program in the first three months of 2026 repurchasing approximately 2.9 million Ordinary Shares for total consideration of $0.3 billion, compared to 3.2 million Ordinary Shares repurchased for total consideration of $0.3 billion in the first three months of 2025. The Company is pleased to announce that it is commencing an additional $0.3 billion tranche to be completed no later than July 28, 2026.

2026 Full Year Outlook

We are reaffirming our financial guidance reflecting a strong start to the year as well as the net impact of divestitures and acquisitions agreed in the year to date. We continue to expect favorable underlying demand across our key end-markets, underpinned by significant public investment in infrastructure and continued reindustrialization activity. Within the residential sector we anticipate resilient repair and remodel activity while the new-build segment is expected to remain subdued. Assuming normal seasonal weather patterns and absent any further major dislocations in the geopolitical or macroeconomic environment, CRH's superior strategy, connected portfolio and leading positions of scale in attractive high-growth markets, together with our strong and flexible balance sheet, are expected to underpin another year of growth and value creation in 2026.

2026 Guidance (i)

(in $ billions, except per share data)

Low

High

Net income (ii)

3.9

4.1

Adjusted EBITDA*

8.1

8.5

Diluted EPS (ii)

$5.60

$6.05

Capital expenditure

2.8

3.0

(i) The 2026 guidance does not assume any significant one-off or non-recurring items, including the impact of further potential changes to global trade policies, impairments or other unforeseen events.

(ii) 2026 Net income and diluted EPS are based on approximately $0.7 billion of interest expense, net, an effective tax rate of approximately 24% and a year-to-date average of approximately 675 million diluted common shares outstanding.

Q1 2026 Conference Call

CRH will host a conference call and webcast presentation at 8:00 a.m. (EDT) on Thursday, April 30, 2026, to discuss its Q1 2026 results and outlook. Registration details are available on www.crh.com/investors. Upon registration, a link to join the call and dial-in details will be made available. The accompanying investor presentation will be available on the investor section of the CRH website in advance of the conference call, and a recording of the conference call will be made available afterwards.

About CRH

CRH is the leading provider of building materials critical to modernizing infrastructure. With our team of 83,000 people across 4,000 locations, our unmatched scale, connected portfolio, and deep local relationships make us the partner of choice for transportation, water, and reindustrialization projects, shaping communities for a better tomorrow. CRH (NYSE: CRH) is a member of the S&P 500 Index. For more information, visit www.crh.com.

Appendices

Appendix 1 - Results Of Operations

Three months ended March 31, 2026

Americas Materials Solutions

Analysis of Change

in $ millions

Q1 2025

Currency

Acquisitions

Divestitures

Organic

Q1 2026

% change

Total revenues

2,243

+6

+269

(5)

+211

2,724

+21%

Adjusted EBITDA

59

(1)

+35

+5

+5

103

+75%

Adjusted EBITDA margin

2.6%

3.8%

Americas Materials Solutions’ Total revenues were 21% ahead of the first quarter of 2025, driven by favorable underlying demand and contributions from acquisitions.

In Essential Materials, Total revenues increased by 31%, reflecting strong underlying demand across most regions as well as contributions from acquisitions. Aggregates volumes increased by 14% year-over-year, while pricing declined by 1%, reflecting geographic and project mix-effects. Cement volumes were 10% ahead of the prior year, while pricing was 1% behind.

In Road Solutions, Total revenues were 16% ahead of the prior year, driven by a strong start to the year due to robust project activity. Asphalt volumes increased by 13%, while pricing was in line with the prior year. Readymixed concrete volumes increased by 12%, with pricing up 4% over the same period. Paving and construction revenues increased by 16%, supported by strong project execution, backlog conversion, and contributions from acquisitions.

Adjusted EBITDA for Americas Materials Solutions was 75% ahead of the prior year, driven by strong underlying demand, disciplined cost management, and contributions from acquisitions. Adjusted EBITDA margin was 120bps ahead of the first quarter of 2025.

Americas Building Solutions

Analysis of Change

in $ millions

Q1 2025

Currency

Acquisitions

Divestitures

Organic

Q1 2026

% change

Total revenues

1,682

+3

+18

–

(35)

1,668

(1%)

Adjusted EBITDA

287

–

+2

–

(2)

287

—

Adjusted EBITDA margin

17.1%

17.2%

Americas Building Solutions' Total revenues were 1% behind the first quarter of 2025, due to subdued new-build residential demand and adverse weather conditions in certain markets, partly offset by contributions from acquisitions.

In Building & Infrastructure Solutions, Total revenues were 4% ahead of the first quarter of 2025, driven by strong demand in our utility infrastructure markets.

In Outdoor Living Solutions, Total revenues were 3% behind the prior year period, as subdued new-build residential demand and adverse weather impacted activity levels.

Adjusted EBITDA for Americas Building Solutions was in line with the first quarter of 2025, as strong cost control and operational efficiencies offset cost inflation and subdued new-build residential demand. Adjusted EBITDA margin was 10bps ahead of the prior year period.

International Solutions

Analysis of Change

in $ millions

Q1 2025

Currency

Acquisitions

Divestitures

Organic

Q1 2026

% change

Total revenues

2,831

+257

+161

(176)

(95)

2,978

+5%

Adjusted EBITDA

149

+7

+19

+19

+2

196

+32%

Adjusted EBITDA margin

5.3%

6.6%

International Solutions' Total revenues were 5% ahead of the first quarter of 2025, as contributions from acquisitions, positive pricing momentum, and currency tailwinds more than offset weather-impacted volumes and the impact of divestitures.

In Essential Materials, Total revenues were 12% ahead of the comparable period in 2025. Aggregates volumes were 8% ahead of the prior year period, supported by acquisitions, while cement volumes were in line with the prior year. Aggregates pricing was in line with the prior year period, while cement pricing was 3% ahead.

In Road Solutions, Total revenues were in line with the comparable period in 2025, impacted by divestitures. Readymixed concrete volumes were 2% ahead of the prior year period, supported by acquisitions, while pricing increased by 3% year-over-year. Asphalt volumes and prices were 8% and 5% ahead of the comparable period in 2025, respectively, supported by higher activity levels in Western Europe.

Within Building & Infrastructure Solutions and Outdoor Living Solutions, Total revenues were 4% ahead of the comparable period in 2025, with currency tailwinds more than offsetting the impact of divestitures.

Adjusted EBITDA in International Solutions was 32% ahead of the first quarter of 2025, benefiting from positive pricing momentum, improved operational efficiencies and contributions from acquisitions. Adjusted EBITDA margin increased by 130bps compared to the prior year period.

Appendix 2 - Financial Statements

The following financial statements are an extract of the Company’s Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP for the three months ended March 31, 2026, and do not present all necessary information for a complete understanding of the Company's financial condition as of March 31, 2026. The full Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP for the three months ended March 31, 2026, including notes thereto, will be included as a part of the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC).

Condensed Consolidated Statements of Income (Unaudited)

(in $ millions, except share and per share data)

  Three months ended

March 31

2026

2025

Product revenues

6,234

5,612

Service revenues

1,136

1,144

Total revenues

7,370

6,756

Cost of product revenues

(4,251)

(3,826)

Cost of service revenues

(1,074)

(1,093)

Total cost of revenues

(5,325)

(4,919)

Gross profit

2,045

1,837

Selling, general and administrative expenses

(2,057)

(1,833)

Gain on disposal of long-lived assets

22

14

Loss on impairments

(48)

–

Operating (loss) income

(38)

18

Interest income

21

37

Interest expense

(203)

(181)

Other nonoperating expense, net

(4)

(20)

Loss from operations before income tax benefit and loss from equity method investments

(224)

(146)

Income tax benefit

55

58

Loss from equity method investments

(11)

(10)

Net loss

(180)

(98)

Net loss attributable to noncontrolling interests

4

4

Net loss attributable to CRH

(176)

(94)

Loss per share attributable to CRH

Basic

($0.27)

($0.15)

Diluted

($0.27)

($0.15)

Weighted average common shares outstanding

Basic

668.5

676.7

Diluted

668.5

676.7

Condensed Consolidated Balance Sheets (Unaudited)

(in $ millions, except share data)

  March 31

December 31

March 31

2026

2025

2025

Assets

Current assets:

Cash and cash equivalents

3,240

4,096

3,352

Restricted cash

40

51

–

Accounts receivable, net

5,213

5,178

5,141

Inventories

5,058

5,251

4,960

Assets held for sale

1,811

–

–

Other current assets

877

678

789

Total current assets

16,239

15,254

14,242

Property, plant and equipment, net

24,657

24,937

22,179

Equity method investments

487

502

732

Goodwill

12,592

13,099

11,475

Intangible assets, net

1,956

2,048

1,208

Operating lease right-of-use assets, net

1,274

1,471

1,272

Other noncurrent assets

962

1,018

813

Total assets

58,167

58,329

51,921

Liabilities, redeemable noncontrolling interests and shareholders’ equity

Current liabilities:

Accounts payable

2,947

3,263

2,777

Accrued expenses

2,143

2,196

2,270

Current portion of long-term debt

2,478

1,175

1,458

Operating lease liabilities

247

286

247

Liabilities held for sale

428

–

–

Other current liabilities

1,968

1,834

1,960

Total current liabilities

10,211

8,754

8,712

Long-term debt

16,071

16,478

14,213

Deferred income tax liabilities

3,301

3,511

3,141

Noncurrent operating lease liabilities

1,066

1,232

1,075

Other noncurrent liabilities

2,973

2,876

2,423

Total liabilities

33,622

32,851

29,564

Commitments and contingencies

Redeemable noncontrolling interests

422

430

379

Shareholders’ equity

Preferred stock, €1.27 par value, 150,000 shares authorized and 50,000 shares issued and outstanding for 5% preferred stock and 872,000 shares authorized, issued and outstanding for 7% 'A' preferred stock, as of March 31, 2026, December 31, 2025, and March 31, 2025

1

1

1

Common stock, €0.32 par value, 1,250,000,000 shares authorized; 704,021,684, 706,946,142 and 715,487,343 issued and outstanding, as of March 31, 2026, December 31, 2025, and March 31, 2025 respectively

285

286

289

Treasury stock, at cost (35,793,257, 38,315,792 and 38,850,691 shares as of March 31, 2026, December 31, 2025 and March 31, 2025 respectively)

(1,905)

(2,016)

(2,038)

Additional paid-in capital

250

397

298

Accumulated other comprehensive loss

(353)

(257)

(806)

Retained earnings

24,793

25,593

23,375

Total shareholders’ equity attributable to CRH shareholders

23,071

24,004

21,119

Noncontrolling interests

1,052

1,044

859

Total equity

24,123

25,048

21,978

Total liabilities, redeemable noncontrolling interests and equity

58,167

58,329

51,921

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in $ millions)

  Three months ended

March 31

2026

2025

Cash Flows from Operating Activities:

Net loss

(180)

(98)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation, depletion, and amortization

576

477

Loss on impairments

48

–

Share-based compensation

29

32

(Gain) loss on disposals from businesses and long-lived assets, net

(16)

1

Deferred tax (benefit) expense

(160)

4

Loss from equity method investments

11

10

Pension and other postretirement benefits net periodic benefit cost

4

6

Non-cash operating lease costs

83

59

Other items, net

9

(14)

Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:

Accounts receivable, net

(478)

(268)

Inventories

(156)

(139)

Accounts payable

(287)

(503)

Operating lease liabilities

(86)

(78)

Other assets

(131)

(210)

Other liabilities

128

72

Pension and other postretirement benefits contributions

(10)

(10)

Net cash used in operating activities

(616)

(659)

Cash Flows from Investing Activities:

Purchases of property, plant and equipment, and intangibles

(601)

(645)

Acquisitions, net of cash acquired

(126)

(585)

Proceeds from divestitures

6

36

Proceeds from disposal of long-lived assets

28

35

Distributions received from equity method investments

–

9

Settlements of derivatives

(24)

20

Deferred divestiture consideration received

–

36

Other investing activities, net

(5)

130

Net cash used in investing activities

(722)

(964)

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in $ millions)

  Three months ended

March 31

2026

2025

Cash Flows from Financing Activities:

Proceeds from debt issuances

1,212

3,017

Payments on debt

(207)

(1,533)

Settlements of derivatives

(15)

15

Payments of finance lease obligations

(37)

(21)

Deferred and contingent acquisition consideration paid

(12)

(11)

Distributions to noncontrolling and redeemable noncontrolling interests

(15)

(17)

Transactions involving noncontrolling interests

(24)

–

Repurchases of common stock

(332)

(310)

Amounts related to employee share plans

2

1

Net cash provided by financing activities

572

1,141

Effect of exchange rate changes on cash and cash equivalents, including restricted cash

(48)

75

Decrease in cash and cash equivalents, including restricted cash

(814)

(407)

Cash and cash equivalents and restricted cash at the beginning of period

4,147

3,759

Cash and cash equivalents and restricted cash at the end of period

3,333

3,352

Supplemental cash flow information:

Cash paid for interest (including finance leases)

160

63

Cash paid for income taxes

39

134

Reconciliation of cash and cash equivalents and restricted cash

Cash and cash equivalents presented in the Condensed Consolidated Balance Sheets

3,240

3,352

Cash and cash equivalents included in Assets held for sale

53

–

Restricted cash presented in the Condensed Consolidated Balance Sheets

40

–

Total cash and cash equivalents and restricted cash presented in the Condensed Consolidated
Statements of Cash Flows

3,333

3,352

Appendix 3 - Non-GAAP Reconciliation and Supplementary Information

CRH uses a number of non-GAAP financial measures to monitor financial performance. These measures are referred to throughout the discussion of our reported financial position and operating performance on a continuing operations basis unless otherwise defined and are measures which are regularly reviewed by CRH management. These financial measures may not be uniformly defined by all companies and accordingly may not be directly comparable with similarly titled measures and disclosures by other companies.

Certain information presented is derived from amounts calculated in accordance with U.S. GAAP but is not itself an expressly permitted GAAP measure. The non-GAAP financial measures as summarized below should not be viewed in isolation or as an alternative to the most directly comparable GAAP measure.

Adjusted EBITDA: Adjusted EBITDA is defined as earnings from continuing operations before interest, taxes, depreciation, depletion, amortization, Loss on impairments, gain/loss on divestitures and investments, Income/loss from equity method investments, substantial acquisition-related costs and pension expense/income excluding current service cost component. It is quoted by management in conjunction with other GAAP and non-GAAP financial measures to aid investors in their analysis of the performance of the Company. Adjusted EBITDA by segment is monitored by management in order to allocate resources between segments and to assess performance.

Adjusted EBITDA margin is calculated by expressing Adjusted EBITDA as a percentage of Total revenues.

Reconciliation to its most directly comparable GAAP measure is presented below:

Three months ended

March 31

in $ millions

2026

2025

Net loss

(180)

(98)

Loss from equity method investments

11

10

Income tax benefit

(55)

(58)

Loss on divestitures and investments (i)

6

26

Pension income excluding current service cost component (i)

(5)

(4)

Other interest, net (i)

3

(2)

Interest expense

203

181

Interest income

(21)

(37)

Depreciation, depletion and amortization

576

477

Loss on impairments (ii)

48

–

Adjusted EBITDA

586

495

Total revenues

7,370

6,756

Net loss margin

(2.4%)

(1.5%)

Adjusted EBITDA margin

8.0%

7.3%

(i) Loss on divestitures and investments, pension income excluding current service cost component and other interest, net have been included in Other nonoperating expense, net in the Condensed Consolidated Statements of Income.

(ii) For the three months ended March 31, 2026, Loss on impairments totaled $48 million, related to the International Solutions segment.

Reconciliation to the most directly comparable GAAP measure for the mid-point of the 2026 Adjusted EBITDA guidance is presented below:

in $ billions

2026

Mid-Point

Net income

4.0

Income tax expense

1.3

Interest expense, net

0.7

Depreciation, depletion and amortization

2.3

Adjusted EBITDA

8.3

Net Debt: Net Debt is used by management as it gives additional insight into the Company’s current debt position less available cash. Net Debt is provided to enable investors to see the economic effect of gross debt, related hedges and cash and cash equivalents in total. Net Debt comprises short and long-term debt, finance lease liabilities, cash and cash equivalents and current and noncurrent derivative financial instruments (net).

Reconciliation to its most directly comparable GAAP measure is presented below:

March 31

December 31

March 31

in $ millions

2026

2025

2025

Short and long-term debt

(18,549)

(17,653)

(15,671)

Cash and cash equivalents (i)

3,293

4,096

3,352

Finance lease liabilities (i)

(592)

(534)

(336)

Derivative financial instruments (net)

20

(60)

(31)

Net Debt

(15,828)

(14,151)

(12,686)

  (i) Cash and cash equivalents and Finance lease liabilities as of March 31, 2026, include $53 million and $26 million, respectively, that have been reclassified as held for sale.

Organic Revenue and Organic Adjusted EBITDA: Because of the impact of acquisitions, divestitures, currency exchange translation and other non-recurring items on reported results each reporting period, CRH uses organic revenue and organic Adjusted EBITDA as additional performance indicators to assess performance of pre-existing (also referred to as underlying, like-for-like or ongoing) operations each reporting period.

Organic revenue and organic Adjusted EBITDA are arrived at by excluding the incremental revenue and Adjusted EBITDA contributions from current and prior year acquisitions and divestitures, the impact of exchange translation, and the impact of any one-off items. Changes in organic revenue and organic Adjusted EBITDA are presented as additional measures of revenue and Adjusted EBITDA to provide a greater understanding of the performance of the Company. Organic change % is calculated by expressing the organic movement as a percentage of the prior year (adjusted for currency exchange effects). A reconciliation of the changes in organic revenue and organic Adjusted EBITDA to the changes in Total revenues and Adjusted EBITDA by segment, is presented in Appendix 1.

Diluted EPS pre‑impairment: Diluted EPS pre‑impairment is a measure of the Company's profitability per share from continuing operations excluding any Loss on impairments (which is non-cash) and the related tax impact of such impairments. It is used by management to evaluate the Company's underlying profit performance and its own past performance. Diluted EPS information presented on a pre‑impairment basis is useful to investors as it provides an insight into the Company's underlying performance and profitability. Diluted EPS pre‑impairment is calculated as Net income (loss) adjusted for (i) Net (income) loss attributable to redeemable noncontrolling interests (ii) Net (income) loss attributable to noncontrolling interests (iii) adjustment of redeemable noncontrolling interests to redemption value and excluding any Loss on impairments (and the related tax impact of such impairments) divided by the diluted weighted average number of common shares outstanding for the year.

Reconciliation to its most directly comparable GAAP measure is presented below:

Three months ended

March 31

in $ millions, except share and per share data

2026

Per Share

- diluted

2025

Per Share

- diluted

Weighted average common shares outstanding – diluted

668.5

676.7

Net loss

(180)

($0.27)

(98)

($0.15)

Net loss attributable to noncontrolling interests

4

$0.01

4

$0.01

Adjustment of redeemable noncontrolling interests to redemption value

(7)

($0.01)

(7)

($0.01)

Net loss attributable to CRH for EPS

(183)

($0.27)

(101)

($0.15)

Impairment of property, plant and equipment and intangible assets

48

$0.07

—

—

Net loss attributable to CRH for EPS – pre-impairment (i)

(135)

($0.20)

(101)

($0.15)

(i) Reflective of CRH’s share of impairment of property, plant and equipment and intangible assets ($48 million and $nil million, respectively, for the three months ended March 31, 2026 and March 31, 2025).

Appendix 4 - Disclaimer/Forward-Looking Statements

In reliance upon the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, CRH is providing the following cautionary statement.

This document contains statements that are, or may be deemed to be, forward-looking statements with respect to the financial condition, results of operations, business, viability and future performance of CRH and certain of the plans and objectives of CRH. These forward-looking statements may generally, but not always, be identified by the use of words such as “will”, “anticipates”, “should”, “could”, “would”, “targets”, “aims”, “may”, “continues”, “expects”, “is expected to”, “estimates”, “believes”, “intends” or similar expressions. These forward-looking statements include all matters that are not historical facts or matters of fact at the date of this document.

In particular, the following, among other statements, are all forward-looking in nature: plans and expectations regarding outlook for 2026, including market dynamics and demand among CRH's platforms; plans and expectations regarding public investment in infrastructure and reindustrialization activity; plans and expectations regarding pricing momentum, costs, demand, and trends in residential and non-residential markets and macroeconomic and other market trends and dynamics in key end-markets and other regions where CRH operates; expectations with respect to the impact of further potential changes to global trade policies; plans and expectations regarding acquisitions, including the Axius Water acquisition, and divestitures, including the construction accessories and lawn and garden operations, and the timing and resulting synergies, benefits and contributions, respectively, thereof; statements regarding the M&A pipeline and other value-accretive opportunities; statements regarding the reallocation of capital, including the expected benefits of the related growth capital expenditure projects; plans and expectations regarding return of cash to shareholders, including the timing, consistency and amount of share buybacks and dividends; expectations regarding CRH's credit rating with each of the three main ratings agencies; and plans and expectations regarding CRH's 2026 full year performance, including net income, Adjusted EBITDA, diluted EPS, capital expenditures, assumed interest expense and assumed effective tax rate.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future and reflect the Company’s current expectations and assumptions as to such future events and circumstances that may not prove accurate. You are cautioned not to place undue reliance on any forward-looking statements. These forward-looking statements are made as of the date of this document. The Company expressly disclaims any obligation or undertaking to publicly update or revise these forward-looking statements other than as required by applicable law.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, certain of which are beyond our control, and which include, but are not limited to: economic and financial conditions, including changes in interest rates, inflation, price volatility and/or labor and materials shortages; demand for infrastructure, residential and non-residential construction and our products in geographic markets in which we operate; increased competition and its impact on prices and market position; increases in energy, labor and/or other raw materials costs; adverse changes to laws and regulations, including in relation to climate change; the impact of unfavorable weather; investor and/or consumer sentiment regarding the importance of sustainable practices and products; availability of public sector funding for infrastructure programs; political uncertainty, including as a result of political and social conditions in the jurisdictions CRH operates in, or adverse political developments, including the ongoing geopolitical conflicts in Ukraine and the Middle East; failure to complete or successfully integrate acquisitions or make timely divestitures; cyber-attacks and exposure of associates, contractors, customers, suppliers and other individuals to health and safety risks, including due to product failures. Additional factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those expressed by the forward-looking statements in this report including, but not limited to, the risks and uncertainties described herein and in “Risk Factors” in our 2025 Form 10-K and in our other filings with the SEC.

CRH plc (CRH) Q1 2026 Earnings Call Transcript